Quantitative tests of albendazole resistance in beta-tubulin mutants

J.B. Collins,Skyler A. Stone,Emily J. Koury,Anna G. Paredes,Fiona Shao,Crystal Lovato,Michael Chen,Richelle Shi,Anwyn Y. Li,Isa Candal,Khadija Al Moutaa,Nicolas Moya,Erik C. Andersen
DOI: https://doi.org/10.1101/2024.04.11.589070
2024-04-13
Abstract:Benzimidazole (BZ) anthelmintics are among the most important treatments for parasitic nematode infections in the developing world. Widespread BZ resistance in veterinary parasites and emerging resistance in human parasites raise major concerns for the continued use of BZs. Knowledge of the mechanisms of resistance is necessary to make informed treatment decisions and circumvent resistance. Benzimidazole resistance has traditionally been associated with mutations and natural variants in the beta-tubulin gene and orthologs in parasitic species. However, variants in alone do not explain the differences in BZ responses across parasite populations. Here, we examine the roles of five beta-tubulin genes ( , , , , and ) to identify the role each gene plays in BZ response. We generated strains with a loss of each beta-tubulin gene, as well as strains with a loss of , , , or in a genetic background that also lacks to test beta-tubulin redundancy in BZ response. We found that only the individual loss of conferred a substantial level of BZ resistance, although the loss of was found to confer a small benefit in the presence of albendazole (ABZ). The loss of was found to confer an almost complete rescue of animal development in the presence of 30 µM ABZ, likely explaining why no additive effects caused by the loss of a second beta-tubulin were observed. We demonstrate that is the only beta-tubulin gene in where loss confers substantial BZ resistance.
Molecular Biology
What problem does this paper attempt to address?